RxDoctor Payments Data

Lee Klein, MD

Ophthalmology · Plantation, FLNPI 1932184082

Payments from drug & device makers

$4,115in general payments, 2019–2025

Across 97 payments — averaging $42.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$889
  • AbbVie$629
  • Amgen$539
  • Johnson & Johnson Surgical Vision, Inc.$465
  • Rxsight Inc$342
  • Biotissue Holdings Inc.$277
  • plus $975 from 16 others

What the payments were for

  • Food & beverage$4,07099%
  • Gifts$451%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,115 in reported general payments places this provider in the 65th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$302,026
Medicare patients
1,112
Services billed
2,997

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine35$21,129
XiidraLifitegrast23$14,767
LumiganBimatoprost22$7,440
RhopressaNetarsudil Mesylate13$6,932
Travoprost15$3,673
LotemaxLoteprednol Etabonate11$2,657
Tobramycin-DexamethasoneTobramycin/Dexamethasone64$2,575
Latanoprost252$2,417
Prednisolone Acetate53$1,661
Brimonidine Tartrate27$1,217
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat47$913
Fluorometholone12$902
ErythromycinErythromycin Base25$249
Dorzolamide Hcl17$238
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav30$209

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$629$28,56957 claims
Bausch & Lomb Americas Inc.Xiidra$159$14,76723 claims
Aerie Pharmaceuticals, Inc.Rhopressa$106$6,93213 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax$23$2,65711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Plantation

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →